Physician profile
David A Robl
NPI 1598873655
$6,988.19
in general payments reported to CMS, 2019-2025
43 companies · $711 in 2025
The $711 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,293 · 2020: $652 · 2021: $1,528 · 2022: $1,348 · 2023: $617 · 2024: $839 · 2025: $711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,167.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,003.05 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $848.25 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $554.16 | 2019-2025 | Jardiance, Ofev |
| Lilly USA, LLC | $533.51 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $532.24 | 2019-2024 | Vraylar, Ubrelvy |
| Amgen INC. | $524.85 | 2019-2025 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $469.00 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $190.93 | 2021-2025 | Intellis Adaptivestim, Symplicity G3 |
| Biohaven Pharmaceutical Holding Company LTD. | $180.16 | 2022 | |
| Merck Sharp & Dohme LLC | $165.26 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $151.51 | 2021-2022 | |
| Amarin Pharma, INC. | $149.52 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $140.18 | 2021 | |
| Grifols USA, LLC | $138.31 | 2024-2025 | Prolastin-C Liquid |
| Bayer Healthcare Pharmaceuticals INC. | $112.83 | 2021-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Robl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.